{"id":"seasonal-trivalent-influenza-vaccine-anflu","safety":{"commonSideEffects":[{"rate":"10–30","effect":"Injection site pain, redness, or swelling"},{"rate":"5–15","effect":"Myalgia"},{"rate":"5–10","effect":"Headache"},{"rate":"1–5","effect":"Low-grade fever"},{"rate":"5–10","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL2109042","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Seasonal trivalent influenza vaccines contain inactivated or attenuated viral antigens from three circulating influenza strains (typically two A subtypes and one B type). Upon administration, the vaccine triggers both humoral (antibody) and cell-mediated immune responses, enabling the body to recognize and neutralize these specific influenza viruses if encountered naturally, thereby preventing infection or reducing disease severity.","oneSentence":"The vaccine stimulates the immune system to produce antibodies and cellular immunity against three seasonal influenza virus strains.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:37:29.155Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of seasonal influenza caused by influenza A and B viruses"}]},"trialDetails":[{"nctId":"NCT02640989","phase":"PHASE4","title":"Safety and Immunogenicity of Three Seasonal Trivalent Influenza Vaccines in China Military","status":"COMPLETED","sponsor":"Center for Disease Prevention and Control of Beijing Military Region","startDate":"2014-10","conditions":"Influenza","enrollment":292},{"nctId":"NCT02269852","phase":"PHASE4","title":"The Immunogenicity and Safety of 2013-2014 Seasonal Trivalent Influenza Vaccine","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2013-12","conditions":"Influenza","enrollment":182}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Anflu®"],"phase":"marketed","status":"active","brandName":"Seasonal trivalent influenza vaccine, Anflu®","genericName":"Seasonal trivalent influenza vaccine, Anflu®","companyName":"Center for Disease Prevention and Control of Beijing Military Region","companyId":"center-for-disease-prevention-and-control-of-beijing-military-region","modality":"Biologic","firstApprovalDate":"","aiSummary":"The vaccine stimulates the immune system to produce antibodies and cellular immunity against three seasonal influenza virus strains. Used for Prevention of seasonal influenza caused by influenza A and B viruses.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}